 Connection
Halis Akturk to Hypoglycemia
This is a "connection" page, showing publications Halis Akturk has written about Hypoglycemia.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
5.433 |
|
|
|
-
Akturk HK, Karakus KE, Chen B, Walker TC. Exploring the Relationship Between Newly Defined Continuous Glucose Monitoring (CGM) Metrics and the Standard CGM Metrics in 30,000 People with Type 1 Diabetes. Diabetes Technol Ther. 2026 Mar; 28(3):264-270.
Score: 0.663
-
Mason E, Karakus KE, Akturk HK. Barriers to glucagon use in patients with type 1 diabetes. Prim Care Diabetes. 2025 06; 19(3):341-343.
Score: 0.620
-
Karakus KE, Snell-Bergeon J, Mason E, Akturk HK. Improvement in Newly Defined Continuous Glucose Monitor Metrics, Extended Hypoglycemia, and Extended Hyperglycemia With Automated Insulin Delivery Initiation in Adults With Type 1 Diabetes. J Diabetes Sci Technol. 2026 May; 20(3):721-726.
Score: 0.607
-
Akturk HK. Limitations of 14-Day Continuous Glucose Monitoring Sampling for Assessment of Hypoglycemia and Glycemic Variability in Type 1 Diabetes. Diabetes Technol Ther. 2024 07; 26(7):503-508.
Score: 0.574
-
Karakus KE, Shah VN, Klonoff D, Akturk HK. Changes in the glycaemia risk index and its association with other continuous glucose monitoring metrics after initiation of an automated insulin delivery system in adults with type 1 diabetes. Diabetes Obes Metab. 2023 11; 25(11):3144-3151.
Score: 0.551
-
Akturk HK, Herrero P, Oliver N, Wise H, Eikermann E, Snell-Bergeon J, Shah VN. Impact of Different Types of Data Loss on Optimal Continuous Glucose Monitoring Sampling Duration. Diabetes Technol Ther. 2022 10; 24(10):749-753.
Score: 0.513
-
Akturk HK, Dowd R, Shankar K, Derdzinski M. Real-World Evidence and Glycemic Improvement Using Dexcom G6 Features. Diabetes Technol Ther. 2021 03; 23(S1):S21-S26.
Score: 0.468
-
Acciaroli G, Welsh JB, Akturk HK. Mitigation of Rebound Hyperglycemia With Real-Time Continuous Glucose Monitoring Data and Predictive Alerts. J Diabetes Sci Technol. 2022 05; 16(3):677-682.
Score: 0.463
-
Akturk HK, Shah VN. Severe Hypoglycemia in Adults With Type 1 Diabetes After Switching to Insulin Degludec. J Diabetes Sci Technol. 2018 05; 12(3):733-734.
Score: 0.373
-
Akturk HK, Mason E, Cengiz D, Karakus KE, Garg SK. Patient-Reported Adverse Events with Adjunctive Tirzepatide or Semaglutide Treatment in Adults with Type 1 Diabetes. Diabetes Technol Ther. 2026 Jun; 28(6):614-618.
Score: 0.166
-
Riddell MC, Parkin CG, Turner LV, Akturk HK. Potential Applications of Inhaled Insulin in Diabetic Ketoacidosis Prevention and During Exercise: Two Case Presentations. Diabetes Technol Ther. 2026 Feb; 28(1_suppl):31S-37S.
Score: 0.165
-
Peter ME, Rioles N, Liu J, Chapman K, Wolf WA, Nguyen H, Basina M, Akturk HK, Ebekozien O, Perez-Nieves M, Poon JL, Mitchell B. Prevalence of fear of hypoglycemia in adults with type 1 diabetes using a newly developed screener and clinician's perspective on its implementation. BMJ Open Diabetes Res Care. 2023 07; 11(4).
Score: 0.137
-
Akturk HK, Rewers A, Garg SK. SGLT inhibition: a possible adjunctive treatment for type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2018 08; 25(4):246-250.
Score: 0.098
-
Carlson AL, Graham TE, Akturk HK, Liljenquist DR, Bergenstal RM, Sulik B, Shah VN, Sulik M, Zhao P, Briggs P, Sassan-Katchalski R, Pinsker JE. Control-IQ Technology Use in Individuals With High Insulin Requirements: Results From the Multicenter Higher-IQ Trial. J Diabetes Sci Technol. 2024 11; 18(6):1288-1292.
Score: 0.036
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|